Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Commitments (Details)

Commitments (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Feb. 11, 2020
Sep. 06, 2017
Oct. 19, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Commitments (Textual)            
Description on royalty       Under the Innovation Law the rate of royalties varies between 3% to 5% computed based on the revenues from the products that their development was also funded by grants from the IIA. Such commitment is up to the amount of grants received (dollar linked), plus interest at annual rate based on LIBOR.    
Grants total       $ 38    
Royalty expense       43 $ 1,263 $ 34
Operating lease agreements description     The License Agreement provides for the payment of an upfront cash payment of $5,000 to CollPlant, which was paid to CollPlant in November 2018 following effectiveness of the Agreement. In addition, the License Agreement provides for a one-time non-refundable option payments of $3,000 per Option Product ($9,000 in the aggregate), and up to $30,000 of milestone payments payable as follows: (i) $5,000 upon completion of the U.S. facility design, (ii) $5,000 upon completion of production of a specified amount of BioInk, and (iii) $5,000 for FDA marketing approval for each Covered Product (up to $20,000 in the aggregate).      
VAT payables       145 $ 145  
Maximum total royalty amount       $ 8,600    
Israel [Member]            
Commitments (Textual)            
VAT payables   $ 521        
Israel [Member] | Subsequent Event [Member]            
Commitments (Textual)            
Tax pay $ 116          
Tax Contingent Liability [Member] | Israel [Member]            
Commitments (Textual)            
Tax pay   $ 434